Procyon Advisors LLC Has $891,000 Holdings in Zoetis Inc. (NYSE:ZTS)

Procyon Advisors LLC grew its holdings in Zoetis Inc. (NYSE:ZTS) by 3.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,512 shares of the company’s stock after buying an additional 145 shares during the quarter. Procyon Advisors LLC’s holdings in Zoetis were worth $891,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in ZTS. Nelson Van Denburg & Campbell Wealth Management Group LLC grew its holdings in shares of Zoetis by 430.8% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after purchasing an additional 112 shares during the last quarter. VitalStone Financial LLC bought a new stake in Zoetis during the 1st quarter worth about $37,000. Evermay Wealth Management LLC lifted its position in Zoetis by 439.3% during the 1st quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock valued at $25,000 after purchasing an additional 123 shares during the period. Worth Asset Management LLC acquired a new position in Zoetis during the 1st quarter valued at about $26,000. Finally, VisionPoint Advisory Group LLC acquired a new position in Zoetis during the 2nd quarter valued at about $29,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the topic of a number of analyst reports. Jefferies Financial Group reiterated a “buy” rating and issued a $230.00 price target on shares of Zoetis in a research report on Tuesday, December 19th. The Goldman Sachs Group raised their target price on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Piper Sandler raised their target price on shares of Zoetis from $215.00 to $220.00 and gave the stock an “overweight” rating in a report on Tuesday, February 20th. BNP Paribas began coverage on shares of Zoetis in a research note on Thursday, December 7th. They set an “outperform” rating and a $237.00 price target for the company. Finally, Barclays raised their price target on shares of Zoetis from $255.00 to $260.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 14th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $224.33.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction on Monday, March 18th. The stock was sold at an average price of $173.33, for a total transaction of $159,983.59. Following the completion of the sale, the executive vice president now owns 15,723 shares of the company’s stock, valued at $2,725,267.59. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last 90 days, insiders sold 2,209 shares of company stock valued at $408,453. 0.12% of the stock is currently owned by corporate insiders.

Zoetis Stock Performance

ZTS stock traded up $0.57 during midday trading on Thursday, reaching $169.08. 297,821 shares of the company were exchanged, compared to its average volume of 2,687,886. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00. The business has a 50-day moving average price of $186.36 and a two-hundred day moving average price of $182.34. Zoetis Inc. has a one year low of $151.03 and a one year high of $201.92. The firm has a market capitalization of $77.42 billion, a price-to-earnings ratio of 33.24, a price-to-earnings-growth ratio of 2.53 and a beta of 0.87.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The firm had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. During the same period in the prior year, the business posted $1.15 EPS. The firm’s quarterly revenue was up 8.5% compared to the same quarter last year. Equities research analysts forecast that Zoetis Inc. will post 5.8 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be issued a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.02%. The ex-dividend date is Thursday, April 18th. Zoetis’s dividend payout ratio is currently 34.12%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.